

BCBSMT HEDIS® 2014 COMPARISON REPORT - PPO

EFFECTIVENESS OF CARE MEASURES

BCBSMT 2012

BCBSMT 2013

BCBSMT 2014

2013 QC National

2014 QC National

	Num	Denom		Num	Denom	% change	Num	Denom	% change				
Childhood Immunization****			n=849			n=473			n=453				
DTaP	442	849	52.06%	399	473	84.36%	na	379	453	83.66%	-0.82%	80.00%	80.30%
Hib	591	849	69.61%	426	473	90.06%	na	411	453	90.73%	0.74%	88.30%	88.10%
IPV	522	849	61.48%	426	473	90.06%	na	414	453	91.39%	1.47%	86.30%	86.20%
PCV	470	849	55.36%	390	473	82.45%	na	391	453	86.31%	4.68%	78.90%	78.30%
HepB	400	849	47.11%	411	473	86.89%	na	403	453	88.96%	2.38%	77.30%	76.80%
MMR	685	849	80.68%	421	473	89.01%	na	410	453	90.51%	1.69%	88.30%	88.70%
VZV	656	849	77.27%	398	473	84.14%	na	394	453	86.98%	3.37%	88.00%	88.30%
HepA ^	213	849	25.09%	339	473	71.67%	na	330	453	72.85%	1.64%	61.10%	79.30%
Rotavirus	396	849	46.64%	331	473	69.98%	na	330	453	72.85%	4.10%	69.80%	71.90%
Influenza	306	849	36.04%	268	473	56.66%	na	243	453	53.64%	-5.33%	59.80%	61.10%
Combo-1	na	849	na	398	473	84.14%	na	358	453	79.03%	-6.08%	na	na
Combo-2	304	849	35.81%	358	473	75.69%	na	343	453	75.72%	0.04%	68.10%	67.50%
Combo-3	293	849	34.51%	339	473	71.67%	na	337	453	74.39%	3.80%	65.80%	66.40%
Combo-4 ^	95	849	11.19%	282	473	59.62%	na	279	453	61.59%	3.30%	na	na
Combo-5	222	849	26.15%	273	473	57.72%	na	276	453	60.93%	5.56%	na	na
Combo-6	144	849	16.96%	229	473	48.41%	na	209	453	46.14%	-4.70%	na	na
Combo-7 ^	82	849	9.66%	252	473	53.28%	na	247	453	54.53%	2.34%	na	na
Combo-8 ^	56	849	6.60%	202	473	42.71%	na	181	453	39.96%	-6.44%	na	na
Combo-9	123	849	14.49%	201	473	42.49%	na	177	453	39.07%	-8.05%	na	na
Combo-10 ^	53	849	6.24%	188	473	39.75%	na	160	453	35.32%	-11.14%	29.50%	38.70%
Adolescent Immunizations****			n=1111			n=471			n=450				
Meningococcal (MCV)	373	1111	33.57%	202	471	42.89%	na	204	450	45.33%	5.70%	57.10%	60.60%
Tdap/Td	668	1111	60.13%	390	471	82.80%	na	353	450	78.44%	-5.26%	69.90%	72.90%
Combo-1	356	1111	32.04%	201	471	42.68%	na	201	450	44.67%	4.67%	54.30%	58.20%
HPV Vaccine for Female Adolescents****			n=571			n=472			n=448				
	50	571	8.76%	43	472	9.11%	na	53	448	11.83%	29.86%	na	10.90%
Appropriate Tx for Children w/ URI			n=1900			n=1484			n=1925				
	1520	1900	80.00%	1184	1484	79.78%	-0.27%	1555	1925	80.78%	1.25%	82.30%	83.20%
Appropriate Testing for Children w/ Pharyngitis			n=1523			n=1102			n=1074				
	1095	1523	71.90%	772	1102	70.05%	-2.56%	756	1074	70.39%	0.48%	78.90%	78.40%
Avoidance of Antibiotic Tx for Adults w/ Acute Bronchitis			n=1356			n=1289			n=1410				
	296	1356	21.83%	270	1289	20.95%	-4.04%	358	1410	25.39%	21.21%	21.40%	23.80%
Colorectal Cancer Screening			n=22,436			n=22,096			n=30,155				
	8437	22,436	37.60%	9186	22,096	41.57%	10.55%	12,324	30,155	40.87%	-1.69%	55.80%	56.50%

EFFECTIVENESS OF CARE MEASURES	BCBSMT 2012		BCBSMT 2013		% change	BCBSMT 2014		% change	2013 QC National	2014 QC National			
	Num	Denom	Num	Denom		Num	Denom						
Breast Cancer Screening^^	n=17,487		n=16,948			n=12,105							
	11,514	17,487	65.84%	11,136	16,948	65.71%	-0.21%	8741	12,105	72.21%	9.90%	66.50%	69.50%
Cervical Cancer Screening^^^	n=21,765		n=16,820			n=19,974							
	15,535	21,765	71.38%	11,964	16,820	71.13%	-0.35%	14,313	19,974	71.66%	0.74%	73.60%	na
Persistence of Beta Blocker Treatment after Heart Attack	n=49		n=46			n=59							
	41	49	83.67%	38	46	82.61%	-1.27%	44	59	74.58%	-9.72%	79.50%	81.40%
Controlling High Blood Pressure	n=na		n=na			n=447							
Blood Pressure < 140/90 mmHg	na	na	na	na	na	na	na	291	447	65.10%	na	57.40%	57.60%
Cholesterol Management for Patients****	n=587		n=461			n=453							
w/ Cardiovascular Conditions													
LDL-screening	436	587	74.28%	373	461	80.91%	8.93%	349	453	77.04%	-4.78%	83.70%	82.60%
Comprehensive Diabetes Care****	n=2805		n=617			n=597							
HbA1c Tested	2370	2805	84.49%	548	617	88.82%	5.12%	545	597	91.29%	2.78%	87.20%	87.30%
Poor HbA1c Control >9.0% *	na	2805	na	220	617	35.66%	na	140	597	23.45%	-34.23%	35.20%	37.60%
HbA1c < 8.0%	na	2805	na	337	617	54.62%	na	389	597	65.16%	19.30%	54.50%	52.90%
HbA1c < 7.0% **	na	2188	na	135	433	31.18%	na	212	470	45.11%	44.67%	36.00%	32.40%
Eye Exam	1011	2805	36.04%	336	617	54.46%	51.09%	325	597	54.44%	-0.03%	48.80%	46.90%
LDL Screening	1921	2805	68.48%	465	617	75.36%	10.05%	459	597	76.88%	2.02%	81.70%	81.30%
LDL Level < 130 mg/dL	na	2805	na	317	617	51.38%	na	354	597	59.30%	15.41%	na	na
LDL Level < 100 mg/dL	na	2805	na	222	617	35.98%	na	243	597	40.70%	13.13%	41.70%	40.80%
Nephropathy Monitored	2036	2805	72.58%	479	617	77.63%	6.96%	489	597	81.91%	5.51%	78.60%	78.80%
Blood Pressure < 140/80 mmHg	na	2805	na	262	617	42.46%	na	277	597	46.40%	9.27%	37.50%	37.60%
Blood Pressure < 140/90 mmHg	na	2805	na	377	617	61.10%	na	418	597	70.02%	14.59%	58.30%	58.50%
Follow-up for Mental Illness	n=167		n=294			n=260							
7 days	80	167	47.90%	146	294	49.66%	3.66%	122	260	46.92%	-5.51%	53.00%	49.80%
30 days	127	167	76.05%	207	294	70.41%	-7.42%	176	260	67.69%	-3.86%	72.20%	69.00%
Antidepressant Medication Management	n=620		n=746			n=1141							
Effective Acute Phase Tx	418	620	67.42%	532	746	71.31%	5.78%	773	1141	67.75%	-5.00%	68.90%	64.30%
Effective Continuation Phase TX	316	620	50.97%	402	746	53.89%	5.73%	593	1141	51.97%	-3.55%	53.40%	48.70%
Follow-Up for Children Prescribed	n=136		n=142			n=160							
ADHD Medication													
Initiation Phase Visit	56	136	41.18%	47	142	33.10%	-19.62%	59	160	36.88%	11.41%	38.10%	38.20%
Continuation Phase	12	32	37.50%	11	37	29.73%	-20.72%	19	33	57.58%	93.66%	44.90%	45.20%
Use of Appropriate Medications for People with Asthma	n=812		n=739			n=810							
Ages 5-11	78	87	89.66%	65	67	97.01%	8.21%	58	60	96.67%	-0.36%	95.70%	96.20%

EFFECTIVENESS OF CARE MEASURES
BCBSMT 2012
BCBSMT 2013
BCBSMT 2014
2013 QC National
2014 QC National

	Num	Denom		Num	Denom	% change	Num	Denom	% change				
Ages 12-18	75	82	91.46%	74	79	93.67%	2.41%	61	71	85.92%	-8.28%	92.20%	93.10%
Ages 19-50	316	364	86.81%	289	345	83.77%	-3.51%	331	391	84.65%	1.06%	87.40%	87.10%
Ages 51-64	256	279	91.76%	224	248	90.32%	-1.56%	265	288	92.01%	1.87%	92.20%	92.00%
Combined	725	812	89.29%	652	739	88.23%	-1.19%	715	810	88.27%	0.05%	90.70%	90.50%
Medications Management for People with Asthma (75%)													
			n=725			n=652				n=715			
Ages 5-11	32	78	41.03%	16	65	24.62%	-40.00%	17	58	29.31%	19.07%	34.50%	42.80%
Ages 12-18	25	75	33.33%	29	74	39.19%	17.57%	22	61	36.07%	-7.97%	34.10%	38.80%
Ages 19-50	109	316	34.49%	107	289	37.02%	7.34%	132	331	39.88%	7.71%	42.10%	47.90%
Ages 51-64	137	256	53.52%	120	224	53.57%	0.10%	148	265	55.85%	4.25%	55.60%	59.80%
Combined	303	725	41.79%	272	652	41.72%	-0.18%	319	715	44.62%	6.95%	43.50%	49.60%
Asthma Medication Ratio													
			n=na			n=736				n=808			
Ages 5-11	na	na	na	52	67	77.61%	na	49	59	83.05%	7.01%	na	89.70%
Ages 12-18	na	na	na	66	79	83.54%	na	45	71	63.38%	-24.14%	na	79.90%
Ages 19-50	na	na	na	230	345	66.67%	na	270	390	69.23%	3.85%	na	71.80%
Ages 51-64	na	na	na	196	248	79.03%	na	240	288	83.33%	5.44%	na	82.90%
Combined	na	na	na	545	736	74.05%	na	604	808	74.75%	0.95%	na	78.40%
Use of Spirometry in the Assessment & Diagnoses of COPD													
			n=195			n=182				n=218			
	60	195	30.77%	68	182	37.36%	21.43%	74	218	33.94%	-9.15%	41.50%	41.00%
Pharmacotherapy Management of COPD Exacerbation													
			n=45			n=40				n=51			
Bronchodilator	30	45	66.67%	30	40	75.00%	12.50%	41	51	80.39%	7.19%	77.70%	78.70%
Systemic Corticosteroid	26	45	57.78%	34	40	85.00%	47.12%	30	51	58.82%	-30.80%	70.80%	72.80%
Chlamydia Screening													
			n=3843			n=5241				n=4704			
Ages 16-20	525	1681	31.23%	792	2233	35.47%	13.57%	633	2004	31.59%	-10.94%	38.90%	37.80%
Ages 21-24	814	2162	37.65%	1157	3008	38.46%	2.16%	976	2700	36.15%	-6.02%	45.50%	45.90%
Combined	1339	3843	34.84%	1949	5241	37.19%	6.73%	1609	4704	34.20%	-8.02%	42.30%	42.20%
Use of Imaging Studies for Low Back Pain													
			n=1797			n=1814				n=2050			
	1465	1797	81.52%	1488	1814	82.03%	0.62%	1672	2050	81.56%	-0.57%	74.20%	74.40%
DMARD Therapy in Rheumatoid Arthritis													
			n=311			n=357				n=417			
	279	311	88.89%	314	357	87.96%	-1.05%	361	417	86.57%	-1.57%	87.20%	87.20%
Annual Monitoring for Patients on Persistent Medications													
			n=9539			n=9623				n=11,386			
ACE/ARB	3833	5254	72.95%	3782	5344	70.77%	-2.99%	4604	6414	71.78%	1.43%	79.20%	80.40%
Anticonvulsant	124	230	53.91%	108	200	54.00%	0.16%	109	209	52.15%	-3.42%	56.30%	56.10%
Digoxin	103	122	84.43%	78	97	80.41%	-4.75%	80	99	80.81%	0.49%	80.60%	82.30%

EFFECTIVENESS OF CARE MEASURES

BCBSMT 2012

BCBSMT 2013

BCBSMT 2014

2013 QC National

2014 QC National

	Num	Denom		Num	Denom		% change	Num	Denom		% change		
Diuretic	2820	3933	71.70%	2833	3982	71.15%	-0.78%	3329	4664	71.38%	0.33%	78.70%	79.90%
Combined	6880	9539	72.12%	6801	9623	70.67%	-2.01%	8122	11,386	71.33%	0.93%	78.50%	79.80%

** Note: For this numerator, a lower rate indicates better performance.*

*** Note: The HbA1c < 7.0% denominator excludes members w/ certain conditions. Please see measure description for a list of conditions.*

****Note: Medical record review was completed on these measures for HEDIS 2013 & 2014, but not HEDIS 2012.*

*****Note: Medical record review was completed on these measures for HEDIS 2013, but not HEDIS 2012 or 2014.*

^Note: The NCQA qualifying dosing requirements for the Hepatis A immunizations series changed from 2 doses in 2012 to 1 dose in 2013 & 2014.

^^ Note: The Breast Cancer Screening age qualifying range for women changed to women age 50-74 years in 2014 from 40-74 years in 2013 & 2012.

^^^ Note: The Cervical Cancer Screening screening frequency in 2014 changed to allow two screening methods. For women who had cervical cytology/HPV co-testing, the screening frequency is extended to every 5 years. For women with only cervical cytology testing, the screening frequency remains every 3 years.

BCBSMT 2012 rates based on 2011 data.

BCBSMT 2013 rates based on 2012 data.

BCBSMT 2014 rates based on 2013 data.

The 2014 QC (Quality Compass®) rate comparisons are from NCQA's *State of Health Care Quality 2014 Report* and reflect 2013 data.

The 2013 QC (Quality Compass®) rate comparisons are from NCQA's *State of Health Care Quality 2013 Report* and reflect 2012 data.